Biocon Pharma Inc. announced the U.S. FDA approval of its Mycophenolic Acid tablets, impacting the competitive landscape by expanding generic options for immunosuppressant therapy. This launch is expected to influence market dynamics for branded formulations by offering a cost-effective alternative to the reference product.